Medication guide: The Full Evidence

How does childhood hayfever differ from adult presentation?

What the research says

Childhood allergic rhinitis differs from adult presentation in several key ways: children more commonly experience intermittent (seasonal) disease with higher classified severity despite lower subjective symptom scores, while adults tend toward persistent, perennial symptoms with greater self-reported burden. Children exhibit a stronger association with atopic comorbidities including asthma, conjunctivitis, atopic dermatitis, otitis media, and adenoid hypertrophy, whereas adults more frequently report sleep disturbance and work productivity loss. Quality of life impacts in children are predominantly expressed through impaired school performance, concentration difficulties, and developmental concerns rather than the occupational and sleep-related impairments dominant in adults.

How it works

The pediatric immune system is in an active sensitization phase, predisposing children to IgE-mediated polysensitization and the sequential progression of atopic march (eczema → rhinitis → asthma), driven by Th2-skewed immune responses and ongoing allergen exposure during critical developmental windows. Anatomical factors unique to children, including Eustachian tube immaturity and adenoidal tissue prominence, amplify nasal obstruction and predispose to middle ear and sinus complications not typically seen in adult disease.

---

Which hayfever treatments are safe during pregnancy?

What the research says

Several hayfever treatments are considered safe during pregnancy, including second-generation antihistamines (loratadine, cetirizine), first-generation antihistamines (chlorpheniramine), and intranasal corticosteroids (particularly budesonide, fluticasone, and mometasone). Large registry studies and meta-analyses involving hundreds of thousands of exposures show no consistent increase in congenital malformations with these agents. Oral decongestants such as pseudoephedrine should be avoided in the first trimester due to associations with gastroschisis and other birth defects, though limited use may be considered in later trimesters under medical supervision.

How it works

Intranasal corticosteroids and topically delivered agents have minimal systemic absorption, limiting fetal exposure, while antihistamines such as loratadine and cetirizine have low placental transfer rates. First-generation antihistamines have a longer safety track record due to decades of use, and their established metabolic profiles reassure against teratogenicity at standard doses.

---

Does breastfeeding reduce allergy risk in children?

What the research says

Evidence from multiple systematic reviews and meta-analyses suggests a modest protective association between breastfeeding (particularly longer duration) and reduced risk of allergic rhinitis in children ≤5 years, as well as asthma in children aged 5–18 years, especially in low- and middle-income countries. However, evidence for protection against other allergic conditions such as atopic dermatitis and food allergy is weaker, more inconsistent, and characterized by high heterogeneity across studies. Overall, the protective effect of breastfeeding on allergy risk is biologically plausible but not yet conclusively established due to significant methodological limitations.

How it works

Breast milk transfers pre-digested allergens bound to maternal antibodies alongside immunomodulatory factors (including secretory IgA), which may prime the infant immune system toward tolerance rather than sensitization. Breastfeeding may also shape the early gut microbiome, supporting immune regulatory pathways that reduce atopic disease susceptibility.

---

What are safe and effective hayfever treatments for children under 12?

What the research says

Second-generation oral antihistamines (cetirizine, loratadine, fexofenadine) and intranasal corticosteroids (mometasone, fluticasone, triamcinolone) are established first-line treatments for allergic rhinitis in children under 12, with strong evidence supporting their safety and efficacy. Intranasal corticosteroids are superior for moderate-to-severe or persistent symptoms, particularly nasal congestion, while antihistamines better address rhinorrhea and itch. Evidence for combined intranasal antihistamine-corticosteroid therapy (e.g., AzeFlu) in children under 12 is emerging but currently limited to only a small number of studies.

How it works

Second-generation antihistamines selectively block peripheral H1 receptors with minimal CNS penetration, reducing histamine-mediated symptoms without significant sedation. Intranasal corticosteroids suppress local eosinophilic inflammation and type 2 immune responses in the nasal mucosa, reducing vascular permeability, mucus production, and congestion.

---

What is the diagnostic accuracy of fever absence as a discriminator between paediatric allergic rhinitis and viral upper-respiratory infection in children aged 3–12?

What the research says

No high-quality paediatric studies have directly evaluated the diagnostic accuracy of fever absence as a stand-alone discriminator between allergic rhinitis (AR) and viral upper respiratory infection (URI) in children aged 3–12 years. Indirect evidence from separate AR and viral URI cohorts suggests that fever absence has high sensitivity (~95%) but poor specificity (~50%) for AR, since afebrile viral URIs are common—particularly beyond the first 2–3 days of illness—while fever is rare (<5%) in confirmed AR. Presence of fever materially increases likelihood of viral or bacterial infection and makes isolated AR unlikely, but afebrile status alone cannot reliably confirm AR given how frequently viral URIs present without fever.

How it works

Allergic rhinitis is a localised Th2/IgE-mediated mucosal process driven by histamine and cytokines (IL-4, IL-5, IL-13) that do not substantially activate systemic pyrogenic pathways, explaining the near-absence of fever. Viral URIs trigger innate immune responses with release of pyrogenic cytokines (IL-1β, TNF-α, IL-6) acting on hypothalamic thermoregulatory centres, though fever may be transient, low-grade, or absent in mild infections or later disease stages, limiting its discriminatory utility.

---

What symptom-duration thresholds (in days) reliably distinguish a common cold from allergic rhinitis in children aged 3–12?

What the research says

No single validated symptom-duration threshold reliably distinguishes a common cold from allergic rhinitis in children aged 3–12 years, but clinically used cutoffs cluster around 14 days: symptoms resolving within 3–14 days are more consistent with viral URI, while symptoms persisting beyond 14–21 days without improvement raise suspicion for allergic rhinitis. The most rigorously defined duration-based criterion is the ARIA classification of persistent allergic rhinitis (symptoms >4 days/week and >4 consecutive weeks), though this classifies AR phenotype rather than directly discriminating from colds.

How it works

Common colds are self-limited by the host's antiviral immune response, typically resolving within 1–2 weeks as viral replication declines; allergic rhinitis is driven by sustained IgE-mediated mast cell activation and eosinophilic inflammation in response to ongoing allergen exposure, producing symptoms that persist as long as exposure continues.

---

Can a brief, structured, parent-administered checklist achieve acceptable sensitivity and specificity for differentiating allergic rhinitis from viral URI at primary-care presentation in children?

What the research says

No validated, parent-administered checklist currently exists with formally reported sensitivity, specificity, PPV, or NPV for differentiating allergic rhinitis from acute viral URI at primary-care presentation in children. Epidemiologic symptom-based case definitions (e.g., ISAAC-derived questionnaires) achieve sensitivity of approximately 70–80% and specificity of 70–85% for AR versus non-AR in school-age children, but these were validated against atopy markers (SPT/sIgE), not acute viral URI as a comparator, and were not designed as real-time triage tools. Physician-based clinical prediction rules using symptom constellations (nasal itch, paroxysmal sneezing, eye symptoms, absence of fever, seasonality) suggest specificity exceeding 80% for AR, but these are not parent-only instruments and lack pediatric-specific diagnostic accuracy data with viral URI as the explicit comparator.

How it works

Allergic rhinitis is driven by IgE-mediated mast cell and eosinophil activation following allergen exposure, producing histamine-mediated itch, sneezing, and watery rhinorrhea without systemic inflammatory features such as fever or myalgia; viral URI, by contrast, triggers innate immune and cytokine cascades that produce systemic symptoms, purulent secretions, and an acute self-limiting course of 7–10 days—features largely absent in AR—providing the biological basis for symptom-based differentiation.